These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 19285872

  • 21. Structure-activity relationship of novel DAPK inhibitors identified by structure-based virtual screening.
    Okamoto M, Takayama K, Shimizu T, Muroya A, Furuya T.
    Bioorg Med Chem; 2010 Apr 01; 18(7):2728-34. PubMed ID: 20206532
    [Abstract] [Full Text] [Related]

  • 22. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD.
    J BUON; 2007 Sep 01; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [Abstract] [Full Text] [Related]

  • 23. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.
    Shimizu H, Yasumatsu I, Hamada T, Yoneda Y, Yamasaki T, Tanaka S, Toki T, Yokoyama M, Morishita K, Iimura S.
    Bioorg Med Chem Lett; 2011 Feb 01; 21(3):904-8. PubMed ID: 21232950
    [Abstract] [Full Text] [Related]

  • 24. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
    Kuck D, Singh N, Lyko F, Medina-Franco JL.
    Bioorg Med Chem; 2010 Jan 15; 18(2):822-9. PubMed ID: 20006515
    [Abstract] [Full Text] [Related]

  • 25. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
    Li HF, Lu T, Zhu T, Jiang YJ, Rao SS, Hu LY, Xin BT, Chen YD.
    Eur J Med Chem; 2009 Mar 15; 44(3):1240-9. PubMed ID: 18947905
    [Abstract] [Full Text] [Related]

  • 26. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening.
    Cheeseright TJ, Holm M, Lehmann F, Luik S, Göttert M, Melville JL, Laufer S.
    J Med Chem; 2009 Jul 23; 52(14):4200-9. PubMed ID: 19489590
    [Abstract] [Full Text] [Related]

  • 27. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A, Reutlinger M, Hähnke V, Hiss JA, Zettl H, Keppner S, Spänkuch B, Schneider P.
    Future Med Chem; 2011 Mar 23; 3(4):415-24. PubMed ID: 21452978
    [Abstract] [Full Text] [Related]

  • 28. Knowledge based identification of potent antitubercular compounds using structure based virtual screening and structure interaction fingerprints.
    Kumar A, Chaturvedi V, Bhatnagar S, Sinha S, Siddiqi MI.
    J Chem Inf Model; 2009 Jan 23; 49(1):35-42. PubMed ID: 19063713
    [Abstract] [Full Text] [Related]

  • 29. Construction and validation of a RET TK catalytic domain by homology modeling.
    Tuccinardi T, Manetti F, Schenone S, Martinelli A, Botta M.
    J Chem Inf Model; 2007 Jan 23; 47(2):644-55. PubMed ID: 17295463
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
    Boppana K, Dubey PK, Jagarlapudi SA, Vadivelan S, Rambabu G.
    Eur J Med Chem; 2009 Sep 23; 44(9):3584-90. PubMed ID: 19321235
    [Abstract] [Full Text] [Related]

  • 32. In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase.
    Brooks WH, McCloskey DE, Daniel KG, Ealick SE, Secrist JA, Waud WR, Pegg AE, Guida WC.
    J Chem Inf Model; 2007 Sep 23; 47(5):1897-905. PubMed ID: 17676832
    [Abstract] [Full Text] [Related]

  • 33. Homology models of the mutated EGFR and their response towards quinazoline analogues.
    Kotra S, Madala KK, Jamil K.
    J Mol Graph Model; 2008 Oct 23; 27(3):244-54. PubMed ID: 18585943
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.
    Golub AG, Yakovenko OY, Bdzhola VG, Sapelkin VM, Zien P, Yarmoluk SM.
    J Med Chem; 2006 Nov 02; 49(22):6443-50. PubMed ID: 17064064
    [Abstract] [Full Text] [Related]

  • 35. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX, Li LL, Zou J, Yang L, Yang JL, Yang SY.
    Eur J Med Chem; 2009 Nov 02; 44(11):4259-65. PubMed ID: 19640613
    [Abstract] [Full Text] [Related]

  • 36. Discovery of small molecule inhibitors of integrin alphavbeta3 through structure-based virtual screening.
    Zhou Y, Peng H, Ji Q, Qi J, Zhu Z, Yang C.
    Bioorg Med Chem Lett; 2006 Nov 15; 16(22):5878-82. PubMed ID: 16982193
    [Abstract] [Full Text] [Related]

  • 37. Considerations in compound database preparation--"hidden" impact on virtual screening results.
    Knox AJ, Meegan MJ, Carta G, Lloyd DG.
    J Chem Inf Model; 2005 Nov 15; 45(6):1908-19. PubMed ID: 16309298
    [Abstract] [Full Text] [Related]

  • 38. Virtual screening to enrich a compound collection with CDK2 inhibitors using docking, scoring, and composite scoring models.
    Cotesta S, Giordanetto F, Trosset JY, Crivori P, Kroemer RT, Stouten PF, Vulpetti A.
    Proteins; 2005 Sep 01; 60(4):629-43. PubMed ID: 16028223
    [Abstract] [Full Text] [Related]

  • 39. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
    Kasam V, Zimmermann M, Maass A, Schwichtenberg H, Wolf A, Jacq N, Breton V, Hofmann-Apitius M.
    J Chem Inf Model; 2007 Sep 01; 47(5):1818-28. PubMed ID: 17727268
    [Abstract] [Full Text] [Related]

  • 40. IKK-beta inhibitors: an analysis of drug-receptor interaction by using molecular docking and pharmacophore 3D-QSAR approaches.
    Lauria A, Ippolito M, Fazzari M, Tutone M, Di Blasi F, Mingoia F, Almerico AM.
    J Mol Graph Model; 2010 Aug 24; 29(1):72-81. PubMed ID: 20537930
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.